Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 20

Sort by

Sort Order Select

Journal Articles

Super-Enhancer-Driven TOX2 Mediates Oncogenesis in Natural Killer/T Cell Lymphoma

Jianbiao Zhou, MDPhD, Sabrina Hui Min Toh, BSc, Kalpnaa Balan, BSc, Tze King Tan, PhD, Yunlu Jia, MD, Jing Quan Lim, PhD, Choon Kiat Ong, PhDBSc, Soon Thye Lim, MBBS, MRCP, Tuan Zea Tan, Siok-Bian Ng, Takaomi Sanda, MD PhD, Wee-Joo Chng, MBBS, PhD FRCPath, FRCP

Blood (2020) 136 (Supplement 1): 17.

https://doi.org/10.1182/blood-2020-136244

Published: 2020

Journal Articles

Results from the International, Multi-Center, Retrospective B-Holistic Study: Describing Treatment Pathways and Outcomes for Classical Hodgkin Lymphoma

Burhan Ferhanoglu, MD, Tae Min Kim, MD PhD, Amado Karduss, MD, David Brittain, MBBCh, FC Path, Cert Clin Haem, Gayane Tumyan, Mubarak Al Mansour, Marta Zerga, MD, Yuqin Song, MD PhD, Silvia Rivas-Vera, MD, Yok Lam Kwong, MD FRCP, Soon Thye Lim, MBBS, MRCP, Su-Peng Yeh, MD, Arif Abdillah, MD, Zhongwen Huang, Mehul Dalal, PhD, Hui Wan, MD PhD, Mark Hertzberg, MBBS PhDFRACP FRCPA

Blood (2020) 136 (Supplement 1): 32–34.

https://doi.org/10.1182/blood-2020-134885

Published: 2020

Journal Articles

Final Analysis of the Ro-CHOP Phase III Study (Conducted by LYSA): Romidepsin Plus CHOP in Patients with Peripheral T-Cell Lymphoma

Blood (2020) 136 (Supplement 1): 32–33.

https://doi.org/10.1182/blood-2020-134440

Published: 2020

Journal Articles

Results of Intercontinental Cooperative Non-Hodgkin T-Cell Lymphoma Prospective Registry Study

Blood (2019) 134 (Supplement_1): 4035.

https://doi.org/10.1182/blood-2019-126637

Published: 2019

Journal Articles

Treatment Outcomes of Early-Stage Natural-Killer/T-Cell Lymphomas Treated with Chemoradiotherapy: Data from 3 Tertiary Cancer Centres in Singapore

Ya Hwee Tan, MBBS, MRCP, Siqin Zhou, MSc, Liu Xin, Soon Thye Lim, MBBS, MRCP, FAMS, Miriam Tao, MBBS, FAMS, FHKAM, FHKCP, MRCP, Daryl Tan, MBBS, MRCP, Michelle Poon, MBBS, MRCP, FRCPATH, Mohamad Farid, MBBS, MMed, MRCP, Colin Phipps Diong, Yuh Shan Lee, Shin-Yeu Ong, MD, Nicholas Francis Grigoropoulos, Kheng Wei Yeoh, MBBS, MSc, MRCP, MPH, FRCR (Clinical Oncology), Nagavalli Somasundaram, MBBS, MRCP, Eileen Yi Ling Poon, MBBS, MRCP, MMED, Jason Yongsheng Chan, MBBS, MRCP, Esther Wei Yin Chang, MD MRCP, Tiffany Tang, MBBS, MRCP

Blood (2019) 134 (Supplement_1): 5274.

https://doi.org/10.1182/blood-2019-125085

Published: 2019

Journal Articles

Daratumumab Monotherapy for Patients with Relapsed or Refractory (R/R) Natural Killer/T-Cell Lymphoma (NKTCL), Nasal Type: Updated Results from an Open-Label, Single-Arm, Multicenter Phase 2 Study

Blood (2019) 134 (Supplement_1): 1568.

https://doi.org/10.1182/blood-2019-123446

Published: 2019

Journal Articles

Interim Analysis Results from an International, Multi-Centre, Non-Interventional Retrospective Study to Describe Treatment Pathways, Outcomes, and Resource Use in Patients with Classical Hodgkin Lymphoma: B-CD30+ Hodgkin Lymphoma International Multi-Centre Retrospective Study of Treatment Practices and Outcomes (B-HOLISTIC)

Burhan Ferhanoglu, MD, Tae Min Kim, Gayane Tumyan, DMSc, MD PhD, Su-Peng Yeh, MD, David Brittain, MBBCh, FC Path, Cert Clin Haem, Amado Karduss, MD, Yok Lam Kwong, MD FRCP, Soon Thye Lim, MBBS, MRCP, FAMS, Mubarak Al Mansour, MD, Silvia Rivas-Vera, MD, Yuqin Song, MD PhD, Marta Zerga, MD, Julie Blair, PhD MD MPhil, Mehul Dalal, PhD, Hui Wan, MD PhD, Mark Hertzberg

Blood (2018) 132 (Supplement 1): 2917.

https://doi.org/10.1182/blood-2018-99-111146

Published: 2018

Journal Articles

A Clinico-Genotypic Prognostic Index for De Novo Composite Diffuse Large B-Cell Lymphoma Arising from Follicular Lymphoma in the Rituximab Era

Ryan Mao Heng Lim, Natalie Pei Xin Chan, Lay Poh Khoo, BSc, Chee Leong Cheng, FRCPA, FRCPath, MBBS, Leonard Tan, MBBS, MRCPath, Eileen Yi Ling Poon, MBBS, MRCP, MMED, Nagavalli Somasundaram, MBBS, MRCP, Mohamad Farid, MBBS, MMed, MRCP, Tiffany Tang, MBBS, MRCP, Miriam Tao, MBBS, FAMS, FHKAM, FHKCP, MRCP, Soon Thye Lim, MBBS, MRCP, FAMS, Jason Yongsheng Chan, MBBS

Blood (2018) 132 (Supplement 1): 5396.

https://doi.org/10.1182/blood-2018-99-114792

Published: 2018

Journal Articles

Prognostic Value of the Novel Mucosal Associated Lymphoid Tissue Prognostic Index (MALT-IPI) in Marginal Zone Lymphoma (MZL) Cases

Blood (2018) 132 (Supplement 1): 2885.

https://doi.org/10.1182/blood-2018-99-118364

Published: 2018

Journal Articles

Time from Diagnosis to Initiation of Curative Chemotherapy Affects Outcomes in DLBCL - Data from a Large Asian Cohort

Colin Phipps, MBBS, MRCP, FRCPath, Yuh Shan Lee, MBBS, MRCP, FRCPath, Chandramouli Nagarajan, MBBS, MD MRCP, Yunxin Chen, MBBS, MRCP, FRCPath, Allan ZK Goh, Lay Poh Khoo, BSc, Kevin Tay, MD, Miriam Tao, MD, Richard Quek, Tiffany Tang, MD, Mohamad Farid, MD, Soon Thye Lim, MBBS, MRCP, Sathish Kumar Gopalakrishnan, FRCPath, Nicholas F Grigoropoulos, MRCP, FRCPath, Yvonne Loh, MBBS, MRCP, Daryl Tan, MBBS, MRCP, William YK Hwang, MBBS, MRCP, FRCP, Yeow Tee Goh, MD

Blood (2016) 128 (22): 1871.

https://doi.org/10.1182/blood.V128.22.1871.1871

Published: 2016

Journal Articles

Safety and Efficacy of Abexinostat, a Pan-Histone Deacetylase (HDAC) Inhibitor, in Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia: Results of an Ongoing Phase 2 Study

Vincent Ribrag, MD, Won Seog Kim, MD PhD, Reda Bouabdallah, MD, Soon Thye Lim, MBBS, MRCP, Bertrand Coiffier, Zakia Felloussi, Ioana Kloos, Ying Luan, PhD, Thorsten Graef, MD PhD, Franck Morschhauser, MD

Blood (2015) 126 (23): 256.

https://doi.org/10.1182/blood.V126.23.256.256

Published: 2015

Journal Articles

A Phase 2 Study of Panobinostat (PAN) in Combination with Bortezomib (BTZ) in Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma (PTCL) or NK/T-Cell Lymphoma (NKL)

Yeow-Tee Goh, MBBS,MMed, William YK Hwang, FRCP, FAMS, MMed, MRCP, MBBS, Colin Phipps Diong, Yap chun Hsien, bsc, Kevin Tay, MD, Soon Thye Lim, MBBS, MRCP, Yuh Shan Lee, MBBS, MRCP, Soo Chin Ng, MD, S Fadilah, MBBS, Won Seog Kim, Daryl Tan, MD

Blood (2014) 124 (21): 503.

https://doi.org/10.1182/blood.V124.21.503.503

Published: 2014

Journal Articles

A Multi-Center, Non-Randomized Phase 2 Study of Ofatumumab in Combination with ICE-Chemotherapy (O-ICE) in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Tiffany Tang, MBBS, MRCP, Cindy Lim, Miriam Tao, MBBS, MRCP, Richard Quek, MBBS, MRCP, Mohamad Farid, Won Seog Kim, MDPhD, Seok Jin Kim, MD PhD, Seong Hyun Jeong, Jong-Ho Won, MD, Nooraisyah Ismail, Soon Thye Lim, MBBS, MRCP

Blood (2014) 124 (21): 5465.

https://doi.org/10.1182/blood.V124.21.5465.5465

Published: 2014

Journal Articles

Prognostic Significance Of rs6773853 Susceptibility Locus In B-Cell Non-Hodgkin’s Lymphoma

Joycelyn Jie Xin Lee, MBBS, Glorijoy Shi En Tan, MBBS, Chee Hian Tan, MBBS, Summer Pan, Chiea Chuen Khor, Jianjun Liu, Jia Nee Foo, Soo Yong Tan, MBBS, MRCPath, Siok Bian Ng, Miriam Tao, MBBS, MRCP, Soon Thye Lim, MBBS, MRCP, Tiffany Tang, MBBS, MRCP

Blood (2013) 122 (21): 4249.

https://doi.org/10.1182/blood.V122.21.4249.4249

Published: 2013

Journal Articles

Prognostic Significance Of JAK3 Activating Mutations In Natural-Killer/T-Cell Lymphomas

Tiffany Tang, MBBS, MRCP, Summer Pan, Ghee Chong Koo, PhD, Soo Yong Tan, MBBS, MRCPath, Cedric Ng, Vikneswari Rajasegaran, Choon Kiat Ong, Leonard Tan, MBBS, MRCPath, Kevin Tay, MD, Miriam Tao, MBBS, MRCP, Richard Quek, MBBS, MRCP, Kheng Wei Yeoh, MD, Bin Tean Teh, MD, PhD, Soon Thye Lim, MBBS, MRCP

Blood (2013) 122 (21): 4337.

https://doi.org/10.1182/blood.V122.21.4337.4337

Published: 2013

Journal Articles

Dual Translocation Is An Independent Poor Prognostic Factor in Diffuse Large B-Cell Lymphoma,

Kevin Tay, MD, Gillianne Lai, Elaine J Chua, Whee Sze Ong, Tiffany Tang, MBBS, MRCP, Richard Quek, MBBS, MRCP, Daryl Tan, MBBS, MRCP, Leonard Tan, MBBS, MRCPath, Miriam Tao, MBBS, MRCP, Soo Yong Tan, MBBS, MRCPath, Soon Thye Lim, MBBS, MRCP

Blood (2011) 118 (21): 3683.

https://doi.org/10.1182/blood.V118.21.3683.3683

Published: 2011

Journal Articles

Gene Expression Profiling Identifies the JAK/STAT and NFκB Pathways to Be Important in Peripheral T-Cell Lymphomas and Natural-Killer T-Cell Lymphomas

Tiffany Tang, MBBS, MRCP, George Allen, Ghee Chong Koo, PhD, Kevin Tay, MD, Daryl Tan, MBBS, MRCP, Richard Quek, MBBS, MRCP, Miriam Tao, MBBS, MRCP, Soo Yong Tan, MBBS, MRCPath, Bin Tean Teh, MD, PhD, Soon Thye Lim, MBBS, MRCP

Blood (2011) 118 (21): 2658.

https://doi.org/10.1182/blood.V118.21.2658.2658

Published: 2011

Journal Articles

Should Intensive Chemotherapy Be Required for All Mantle Cell Lymphoma Patients

Zhen Tang Lao, MBBS, MRCP, Kathleen Khoo, Jasmine Koh, Whee Sze Ong, Tiffany Tang, MBBS, MRCP, Richard Quek, MBBS, MRCP, Leonard Tan, MBBS, MRCPath, Daryl Tan, MBBS, MRCP, Miriam Tao, MBBS, MRCP, Soo Yong Tan, MBBS, MRCPath, Soon Thye Lim, MBBS, MRCP, Kevin Tay, MD

Blood (2011) 118 (21): 5188.

https://doi.org/10.1182/blood.V118.21.5188.5188

Published: 2011

Journal Articles

Follicular Lymphoma with Diffuse Large B-Cell Component At Initial Diagnosis Appears to Be Associated with a Loss of BCL2 Translocation and Inferior Progression Free Survival

Kevin Tay, MD, Yee Siang Shew, MBBS, Yu Lin Gao, Whee Sze Ong, Tiffany Tang, MBBS, MRCP, Richard Quek, MBBS, MRCP, Daryl Tan, MBBS, MRCP, Leonard Tan, MBBS, MRCPath, Miriam Tao, MBBS, MRCP, Soo Yong Tan, MBBS, MRCPath, Soon Thye Lim, MBBS, MRCP

Blood (2011) 118 (21): 1577.

https://doi.org/10.1182/blood.V118.21.1577.1577

Published: 2011

Journal Articles

AIDS Related Small Non-Cleaved (Burkitt or Atypical Burkitt) Lymphoma Versus Diffuse Large Cell Lymphoma in the Pre- and Post-HAART Eras: Significant Differences in Survival.

Soon Thye Lim, MBBS, MRCP, Byron Espina, AB, Anil Tupule, MD, Bharat N. Nathwani, MD, Alexandra M. Levine, MD

Blood (2004) 104 (11): 601.

https://doi.org/10.1182/blood.V104.11.601.601

Published: 2004

NARROW

Super-Enhancer-Driven TOX2 Mediates Oncogenesis in Natural Killer/T Cell Lymphoma

Results from the International, Multi-Center, Retrospective B-Holistic Study: Describing Treatment Pathways and Outcomes for Classical Hodgkin Lymphoma

Final Analysis of the Ro-CHOP Phase III Study (Conducted by LYSA): Romidepsin Plus CHOP in Patients with Peripheral T-Cell Lymphoma

Results of Intercontinental Cooperative Non-Hodgkin T-Cell Lymphoma Prospective Registry Study

Treatment Outcomes of Early-Stage Natural-Killer/T-Cell Lymphomas Treated with Chemoradiotherapy: Data from 3 Tertiary Cancer Centres in Singapore

Daratumumab Monotherapy for Patients with Relapsed or Refractory (R/R) Natural Killer/T-Cell Lymphoma (NKTCL), Nasal Type: Updated Results from an Open-Label, Single-Arm, Multicenter Phase 2 Study

A Clinico-Genotypic Prognostic Index for De Novo Composite Diffuse Large B-Cell Lymphoma Arising from Follicular Lymphoma in the Rituximab Era

Prognostic Value of the Novel Mucosal Associated Lymphoid Tissue Prognostic Index (MALT-IPI) in Marginal Zone Lymphoma (MZL) Cases

Time from Diagnosis to Initiation of Curative Chemotherapy Affects Outcomes in DLBCL - Data from a Large Asian Cohort

Safety and Efficacy of Abexinostat, a Pan-Histone Deacetylase (HDAC) Inhibitor, in Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia: Results of an Ongoing Phase 2 Study

A Phase 2 Study of Panobinostat (PAN) in Combination with Bortezomib (BTZ) in Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma (PTCL) or NK/T-Cell Lymphoma (NKL)

A Multi-Center, Non-Randomized Phase 2 Study of Ofatumumab in Combination with ICE-Chemotherapy (O-ICE) in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Prognostic Significance Of rs6773853 Susceptibility Locus In B-Cell Non-Hodgkin’s Lymphoma

Prognostic Significance Of JAK3 Activating Mutations In Natural-Killer/T-Cell Lymphomas

Dual Translocation Is An Independent Poor Prognostic Factor in Diffuse Large B-Cell Lymphoma,

Gene Expression Profiling Identifies the JAK/STAT and NFκB Pathways to Be Important in Peripheral T-Cell Lymphomas and Natural-Killer T-Cell Lymphomas

Should Intensive Chemotherapy Be Required for All Mantle Cell Lymphoma Patients

Follicular Lymphoma with Diffuse Large B-Cell Component At Initial Diagnosis Appears to Be Associated with a Loss of BCL2 Translocation and Inferior Progression Free Survival

AIDS Related Small Non-Cleaved (Burkitt or Atypical Burkitt) Lymphoma Versus Diffuse Large Cell Lymphoma in the Pre- and Post-HAART Eras: Significant Differences in Survival.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only